Hawaii Biotech
Hawaii Biotech, Inc. (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases. The company has developed proprietary expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. Lead vaccine candidates in clinical development target the West Nile virus and Dengue virus. Additional recombinant protein subunits vaccine candidates produced from this protein production platform are currently under development. In August of 2010, Merck Sharp and Dohme purchased certain assets from including all rights to the dengue virus vaccine developed by the Company.

Site Map

2012 Hawaii Biotech, Inc. | T 808.486.5333 | F 808.792.1343 | info@hibiotech.com

Employee Email Employee Email